Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Hubei Province, Xiangyang, 441021, China.
NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Signal Transduct Target Ther. 2023 Dec 27;8(1):458. doi: 10.1038/s41392-023-01675-2.
In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox.
2022 年，猴痘（曾称天花）在欧美各国发生全球暴发，并迅速传播至 100 多个国家和地区。由于猴痘病毒的快速传播，世界卫生组织宣布该疫情为国际关注的突发公共卫生事件。因此，各国加强了探索治疗策略的力度，旨在对抗感染及其传播。然而，针对猴痘病毒感染的治疗选择仍然有限。迄今为止，仅有少数几种抗病毒化合物被监管机构批准。鉴于猴痘病毒的高突变性，某些突变株已显示出对现有药物干预的耐药性。这突显了开发能够对抗耐药性和潜在生物恐怖主义威胁的新型抗病毒药物的迫切需要。目前，关于猴痘的病理生理学和治疗方法的综合文献还很缺乏。为了解决这个问题，我们进行了一项综述，涵盖了猴痘感染的生理和病理过程，总结了抗猴痘药物的最新进展。我们的分析包括目前在临床环境中使用的已批准药物，以及新发现的具有抗猴痘病毒潜在疗效的小分子化合物和抗体药物。此外，我们从猴痘药物开发的过程中获得了宝贵的经验，包括药物再利用策略、人工智能驱动的药物靶点发现以及临床前药物开发。本综述的目的是为读者提供有关猴痘的最新知识的全面概述。
